相关实验视频

Updated: Jun 12, 2025

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

甲基受体调节器:对炎症性疾病的专利审查和潜在应用 (2021-2024)

Yung-Fong Tsai^1,2, Shun-Chin Yang³, Tsong-Long Hwang^1,4,5,6

¹Department of Anesthesiology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.

Expert opinion on therapeutic patents

|June 4, 2025

概括

本综述审查了近期关于甲基受体 (FPR) 调节器的专利,重点关注FPR1和FPR2. 它对激动剂和对抗剂进行了分类,讨论了它们对炎症疾病的治疗潜力.

科学领域:

免疫学和药理学
G蛋白结合受体研究研究

背景情况:

甲基受体 (FPR) 是免疫反应和炎症的关键调节者.
FPRs与心血管疾病,神经炎症和癌症有关,提供治疗机会.
偏差激动剂提供了一种策略,可以增强治疗效果,同时最大限度地减少副作用.

研究的目的:

从2021-2024年开始,审查和分类在专利中披露的FPR1和FPR2调制剂.
总结这些FPR调节器的潜在临床应用.
确定FPR向药物开发的挑战和未来方向.

主要方法:

使用台湾专利GO展示数据库进行了有针对性的专利搜索.
专利化合物被归类为FPR1或FPR2调节器.
分析的重点是激动剂,抗剂及其报告的特性.

主要成果:

最近披露的专利揭示了各种fpr1和fpr2调节器.
化合物根据它们与FPR1或FPR2的相互作用来分类.
确定了诸如受体交叉反应和物种变异等挑战.

结论:

对偏向激动剂和选择性连接体合成的进一步研究至关重要.
克服配方挑战对于治疗进步至关重要.
准FPR对治疗炎症性疾病具有前景.

关键词:

激进主义者的激进主义者作为一个对抗者的对抗者.有偏见的激进主义.形成受体的形式受体炎症性疾病是一种炎症性疾病.patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent

更多相关视频

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

Screening Peptides that Activate MRGPRX2 using Engineered HEK Cells

Screening Peptides that Activate MRGPRX2 using Engineered HEK Cells

Published on: November 6, 2021

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Inflammatory Response

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...